KMT2A and non-small cell lung carcinoma: To validate our screening results, we first depleted Trx1 or TrxR1 in two NSCLC cell lines (H1299 and Calu-6) (Fig. 2a), both of which are reported to have a deficient Grx-GSH system, to determine the effect of CHK1i treatment.